PR Newswire BiotechOriginal article
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Data ReadoutpositivePositive
AI Analysis
Summary
Kazia Therapeutics reported 100% clinical benefit rate with durable complete metabolic response in six patients with advanced triple-negative breast cancer, with significant reductions in metastasis-associated CTC clusters and no serious adverse events observed.
Clinical Trial Data
Primary Endpoint
Met
Patients
6
Outcome Details
100% clinical benefit rate in initial six patients with durable complete metabolic response, median 83% reduction in metastasis-associated CTC clusters, median 51% reduction in terminally exhausted T cells, no treatment-related serious adverse events
Importance:6/10
Sentiment:
0.85
oncologytriple-negative breast cancerclinical dataearly stageCTC clustersimmunology
Related Companies
Read the original article
Published by PR Newswire Biotech on August 27, 2026 8:01 PM